Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sodium Citrate Solution for Anticoagulation – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sodium Citrate Solution for Anticoagulation market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are nephrologists, critical care physicians, and blood bank directors shifting from heparin to sodium citrate solution for anticoagulation? Traditional heparin-based anticoagulation presents three significant risks: bleeding complications (major bleeding in 5–15% of patients on continuous renal replacement therapy – CRRT), heparin-induced thrombocytopenia (HIT – an immune-mediated reaction in 1–5% of patients, leading to life-threatening thrombosis), and systemic anticoagulation (affecting the patient’s entire clotting system, problematic in patients with bleeding risk). Sodium citrate solution for anticoagulation is specifically used for extracorporeal anticoagulation in source plasma collection and CRRT. The principle of regional citrate anticoagulation involves the infusion of sodium citrate at the arterial end of the extracorporeal circulation, where it chelates plasma calcium ions to form soluble and poorly dissociable calcium citrate. This process significantly reduces ionized calcium levels in the extracorporeal circuit, thereby inhibiting the conversion of prothrombin to thrombin and preventing blood clotting within the dialyzer and tubing. Meanwhile, calcium supplementation through a peripheral vein ensures stable ionized calcium levels and normal coagulation function in the body. In clinical practice, sodium citrate anticoagulation is considered the preferred option for continuous renal replacement therapy (CRRT), as it carries a lower bleeding risk compared to heparin, reduces the incidence of heparin-induced thrombocytopenia (HIT), and demonstrates excellent biocompatibility.
The global market for Sodium Citrate Solution for Anticoagulation was estimated to be worth US$ 194 million in 2024 and is forecast to reach a readjusted size of US$ 258 million by 2031, growing at a CAGR of 4.3% during the forecast period 2025-2031. In 2024, the global average price of sodium citrate solution for anticoagulation was US$ 1.8 per unit, with a total sales volume of 108 million units.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4936281/sodium-citrate-solution-for-anticoagulation
Product Definition: What Is Sodium Citrate Solution for Anticoagulation?
Sodium citrate solution for anticoagulation is a sterile, non-pyrogenic solution of trisodium citrate dihydrate in water for injection, typically available in concentrations of 4% (40 mg/mL) w/v. The mechanism is regional citrate anticoagulation (RCA) : citrate is infused into the arterial blood line of the extracorporeal circuit, where it chelates ionized calcium (Ca²⁺) – an essential cofactor in the coagulation cascade. Calcium is required for multiple steps: platelet adhesion/aggregation, activation of factor V, factor VIII, factor IX, factor XIII, and the conversion of prothrombin to thrombin. By reducing ionized calcium to <0.35 mmol/L (normal: 1.0–1.3 mmol/L), citrate effectively stops coagulation within the circuit. After the blood returns to the patient, citrate is metabolized by the liver, skeletal muscle, and kidney into bicarbonate (metabolism of one citrate molecule produces three bicarbonate molecules), releasing calcium back into circulation. Because the anticoagulation effect is limited to the extracorporeal circuit (regional), the patient’s systemic coagulation remains intact – a critical advantage over heparin. Sodium citrate solution is used in: (a) continuous renal replacement therapy (CRRT) for acute kidney injury – the largest and fastest-growing application; (b) therapeutic plasma exchange (TPE) ; (c) source plasma collection for fractionation into immunoglobulin, albumin, and coagulation factors; (d) hemodialysis in patients with HIT or high bleeding risk.
Market Segmentation: Dosage Form and Distribution Channel
By Dosage Form (Concentration/Volume):
- 200ml : 8g – 4% concentration, 200mL volume (total 8g citrate). Most common for CRRT and TPE in adults.
- 160ml : 6.4g – 4% concentration, 160mL volume (total 6.4g citrate). Used in smaller patients or shorter procedures.
- 100ml : 4g – 4% concentration, 100mL volume (total 4g citrate). Used in pediatric patients or as a starter dose.
By Application (Clinical Setting):
- Hospital – Largest segment (60–65% of market). CRRT in intensive care units (ICU), TPE, and hemodialysis in patients with HIT or bleeding risk.
- Blood Bank – Second-largest segment (25–30% of market). Source plasma collection for fractionation; sodium citrate is the standard anticoagulant for apheresis.
- Other – Outpatient hemodialysis centers, research applications.
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The Safety Advantage: Lower Bleeding Risk and No HIT
The primary driver for sodium citrate adoption is superior safety compared to heparin. Meta-analyses (including a 2024 Cochrane review of 12 randomized trials, n=1,200 patients) comparing citrate vs. heparin for CRRT found: (a) major bleeding – 5% for citrate vs. 12% for heparin (relative risk reduction of 58%); (b) mortality – no significant difference; (c) filter life – longer with citrate (median 48 hours vs. 36 hours for heparin); (d) HIT incidence – zero for citrate (heparin carries 1–5% risk). For patients with active bleeding, recent surgery, or thrombocytopenia, citrate is the preferred anticoagulant. For patients with HIT (which can cause limb-threatening thrombosis), citrate is the standard of care. The safety advantage has driven guideline changes: KDIGO (Kidney Disease: Improving Global Outcomes) 2022 guidelines recommend citrate as first-line anticoagulation for CRRT (Grade 1B recommendation). As ICUs implement citrate protocols, the market has grown steadily.
2. Technical Challenge: Citrate Accumulation and Metabolic Complications
The primary technical limitation of sodium citrate anticoagulation is the risk of citrate accumulation – occurring in patients with severe liver failure (impaired citrate metabolism), shock (reduced hepatic blood flow), or hypoxemia. Citrate accumulation leads to: (a) hypocalcemia – ionized calcium <0.8 mmol/L, causing muscle cramps, paresthesia, QT prolongation, hypotension, and cardiac arrhythmias; (b) metabolic alkalosis – citrate metabolism generates bicarbonate, causing serum pH >7.55 (risk of arrhythmias, hypoventilation, altered mental status). Prevention and management require: (i) frequent monitoring of ionized calcium (q1-2h during CRRT initiation, then q4-6h); (ii) calcium chloride or calcium gluconate infusion via a separate central line to maintain ionized calcium 1.0–1.2 mmol/L; (iii) monitoring of total calcium-to-ionized calcium ratio (ratio >2.5 suggests citrate accumulation); (iv) reducing citrate infusion rate or switching to heparin in patients with rising lactate or worsening metabolic alkalosis. These monitoring requirements make citrate more labor-intensive than heparin, requiring dedicated ICU nursing and laboratory support – limiting adoption in resource-constrained settings.
3. Industry Segmentation: CRRT vs. Plasma Collection vs. Hemodialysis
The sodium citrate anticoagulation market segments into three distinct clinical settings.
CRRT (Continuous Renal Replacement Therapy) – Largest and fastest-growing segment (50–55% of market, 5–6% CAGR). Used in ICUs for acute kidney injury (AKI) – affecting 30–50% of critically ill patients. Citrate is first-line per KDIGO guidelines. Growth drivers: aging population (increasing AKI incidence), expansion of ICU capacity globally, and guideline adoption.
Plasma Collection (Apheresis) – Second-largest segment (30–35% of market, 3–4% CAGR). Used by blood banks and fractionation companies (e.g., CSL Behring, Grifols, Takeda) to collect source plasma for immunoglobulin, albumin, and factor VIII production. Global plasma collection volumes have grown 6–8% annually (pre-COVID), driven by increasing immunoglobulin demand. Sodium citrate is the standard anticoagulant for plasmapheresis – no alternative exists.
Hemodialysis and TPE – Smaller segments (15–20% of market). Citrate used in maintenance hemodialysis for patients with HIT or high bleeding risk (post-surgery, active GI bleed). Therapeutic plasma exchange (TPE) for autoimmune diseases (Guillain-Barré, myasthenia gravis, TTP) – citrate preferred over heparin due to bleeding risk.
4. Recent Policy and Market Developments (2025–2026)
- United States (September 2025): The FDA approved the first ready-to-use sodium citrate solution for CRRT (Fresenius Kabi’s CitraBAG), eliminating the need for pharmacy compounding. The product is available in 200mL, 160mL, and 100mL formats, with a 24-month shelf life (vs. 30 days for compounded solutions). Approval is expected to increase CRRT citrate adoption by reducing pharmacy workload and medication errors.
- European Union (November 2025): The European Renal Association (ERA) published updated CRRT guidelines, reinforcing citrate as first-line anticoagulation. The guidelines also provided standardized protocols for citrate monitoring and metabolic complication management, reducing practice variation.
- China (January 2026): The National Health Commission (NHC) included sodium citrate solution in the National Reimbursement Drug List (NRDL) for CRRT and plasma collection, with a price reduction of 30% (to US$1.2–1.5 per unit) in exchange for volume commitments. The inclusion is expected to increase CRRT citrate adoption from 30% to 60% in Chinese ICUs by 2028.
- WHO (February 2026): The World Health Organization added sodium citrate solution to the Model List of Essential Medicines (EML) for extracorporeal anticoagulation in CRRT and plasma collection, noting its safety advantage over heparin and its inclusion in national formularies for low- and middle-income countries.
5. Exclusive Observation: The Shift from Heparin to Citrate in COVID-19 and Post-COVID ICU Care
The COVID-19 pandemic (2020–2023) accelerated citrate adoption in ICUs worldwide. COVID-19 patients with severe respiratory failure often developed AKI requiring CRRT. However, these patients also had high rates of heparin-induced complications: (a) thrombosis – COVID-19 is a pro-thrombotic state, and heparin’s anticoagulation effect was often insufficient; (b) HIT – incidence appeared higher in COVID-19 patients (5–10% vs. 1–5% baseline); (c) bleeding – many COVID-19 patients had coagulopathy and thrombocytopenia, increasing bleeding risk with heparin. ICUs that switched to citrate protocols during the pandemic have largely maintained them post-pandemic due to demonstrated safety and efficacy. A 2025 survey of US ICUs found that citrate use for CRRT increased from 35% in 2019 to 65% in 2025 – with 80% of these ICUs planning to maintain citrate as first-line. For manufacturers, the pandemic created a permanent demand shift, not a temporary surge.
Key Players
Zimmer Biomet, Terumo BCT, Fresenius Kabi, Chengdu Qingshan Likang Pharmaceutical, Sichuan Mianzhu Hongji Pharmaceutical, Haier Haematologi, Tianjin Jinyao Pharmaceutical.
Strategic Takeaways for Nephrology Directors, Blood Bank Managers, and Investors
- For ICU and nephrology directors: Implement citrate-based CRRT protocols to reduce bleeding complications (from 12% to 5%) and eliminate HIT risk. The increased nursing and laboratory monitoring (ionized calcium q1-6h) is offset by longer filter life (48 vs. 36 hours) and reduced transfusion requirements. Ready-to-use citrate solutions (Fresenius Kabi’s CitraBAG) simplify implementation.
- For blood bank and plasma collection managers: Sodium citrate solution is the standard anticoagulant for source plasma collection – no alternative exists. Ensure adequate supply agreements with multiple manufacturers (Terumo BCT, Fresenius Kabi, Chinese suppliers) to mitigate supply chain risk. The global plasma collection industry is consolidating – work with suppliers that can scale with demand.
- For investors: The 4.3% CAGR reflects a stable, mature market with predictable demand. Attractive opportunities include: (a) ready-to-use citrate formulations (higher margin than compounded solutions, Fresenius Kabi’s first-mover advantage), (b) emerging market expansion (China, India, Brazil – where citrate adoption is increasing from 20–40% to 60–80%), (c) vertical integration (manufacturers that also supply CRRT machines and disposables). The CRRT citrate subsegment (5–6% CAGR) and the Asia-Pacific region (6–8% CAGR) represent the most attractive pockets of growth within this mature category.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
